Clinical trial BLU-667-2303
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Blueprint Medicines Corporation |
| EudraCT Identifier | 2019-002463-10 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04222972 |
| Inclusion criteria | RET-fusion |
| Last update |